{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:42:08Z","timestamp":1793713328177,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Medication-overuse headache (MOH) remains a leading cause of chronic daily headache globally. Although triptans are the predominant implicated in high-income countries, ergotamine continues to be widely used in many low- and middle-income settings. Comparative data on ergotamine- versus triptan-induced MOH remain limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We analyzed prospective data from the Northern Thai Headache Registry, enrolling patients with ergotamine-MOH, triptan-MOH, or dual-MOH. Demographic and clinical characteristics, treatment outcomes, recurrence rates, and withdrawal symptoms were evaluated over 12 months. Outcomes included changes in Headache Impact Test (HIT-6) scores, recurrence-free survival, and adverse events during withdrawal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 117 MOH patients were included: 61 (52.1%) with ergotamine-MOH, 44 (37.6%) with triptan-MOH, and 12 (10.3%) with dual-MOH. Patients with ergotamine-MOH experienced significantly more withdrawal symptoms compared to those with triptan-MOH (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). In contrast, recurrence rates were highest among dual-MOH patients (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Improvement in HIT-6 scores was observed across all groups, though ergotamine-MOH patients showed slower recovery trajectories. Kaplan\u2013Meier analysis demonstrated a higher risk of recurrence in dual-MOH compared to single-agent MOH.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Ergotamine-induced MOH is linked to more severe withdrawal symptoms, whereas dual-MOH carries the greatest risk of recurrence. These findings highlight the importance of tailored withdrawal strategies and close monitoring, particularly in resource-limited settings where ergotamine remains widely available. They also support policy initiatives aimed at restricting over-the-counter ergotamine and expanding access to safer acute treatment options.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s10194-025-02161-6","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:39Z","timestamp":1759404279000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ergotamine and triptans induced medication-overuse headache: a real-world population-based comparative study from the Northern Thai headache registry"],"prefix":"10.1186","volume":"26","author":[{"given":"Surat","family":"Tanprawate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitti","family":"Thiankhaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watthikorn","family":"Chusilthong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipanee","family":"Muangchean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirinada","family":"Ma-imjai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noratham","family":"Chalapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanokkarn","family":"Teekaput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3019-1210","authenticated-orcid":false,"given":"Chutithep","family":"Teekaput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"issue":"6","key":"2161_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/0333102413512033","volume":"34","author":"ML Westergaard","year":"2014","unstructured":"Westergaard ML, Hansen EH, Gl\u00fcmer C, Olesen J, Jensen RH (2014) Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia 34(6):409\u2013425. https:\/\/doi.org\/10.1177\/0333102413512033","journal-title":"Cephalalgia"},{"key":"2161_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1468-2982.2007.01288.x","volume":"27 3","author":"L Stovner","year":"2007","unstructured":"Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA (2007) The global burden of headache: a Documentation of headache prevalence and disability worldwide. Cephalalgia 27 3:193\u2013210. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01288.x","journal-title":"Cephalalgia"},{"key":"2161_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1468-1331.2011.03497.x","volume":"18 9","author":"S Evers","year":"2011","unstructured":"Evers S, Jensen R (2011) Treatment of medication overuse headache\u2013guideline of the EFNS headache panel. Eur J Neurol 18 9:1115\u20131121. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03497.x","journal-title":"Eur J Neurol"},{"issue":"2","key":"2161_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1212\/con.0000000000001403","volume":"30","author":"P Rizzoli","year":"2024","unstructured":"Rizzoli P (2024) Medication-overuse headache. Continuum 30(2):379\u2013390. https:\/\/doi.org\/10.1212\/con.0000000000001403","journal-title":"Continuum"},{"key":"2161_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/0333102413515338","volume":"34 6","author":"L Bendtsen","year":"2014","unstructured":"Bendtsen L, Munksgaard S, Tassorelli C, Nappi G, Katsarava Z, Lainez M, Leston J, Fadic R, Spadafora S, Stoppini A et al (2014) Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia 34 6:426\u2013433. https:\/\/doi.org\/10.1177\/0333102413515338","journal-title":"Cephalalgia"},{"issue":"9","key":"2161_CR6","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/j.1468-2982.2006.01175.x","volume":"26","author":"P Rossi","year":"2006","unstructured":"Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G (2006) Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia 26(9):1097\u20131105. https:\/\/doi.org\/10.1111\/j.1468-2982.2006.01175.x","journal-title":"Cephalalgia"},{"issue":"11","key":"2161_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40263-013-0081-y","volume":"27","author":"JR Saper","year":"2013","unstructured":"Saper JR, Da Silva AN (2013) Medication overuse headache: history, features, prevention and management strategies. CNS Drugs 27(11):867\u2013877. https:\/\/doi.org\/10.1007\/s40263-013-0081-y","journal-title":"CNS Drugs"},{"issue":"14","key":"2161_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000200117","volume":"98","author":"TJ Schwedt","year":"2022","unstructured":"Schwedt TJ, Hentz JG, Sahai-Srivastava S, Murinova N, Spare NM, Treppendahl C, Martin VT, Birlea M, Digre K, Watson D et al (2022) Patient-centered treatment of chronic migraine with medication overuse: a prospective, randomized, pragmatic clinical trial. Neurology 98(14):e1409\u2013e1421. https:\/\/doi.org\/10.1212\/wnl.0000000000200117","journal-title":"Neurology"},{"issue":"3","key":"2161_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/0333102412462638","volume":"33","author":"K Rabe","year":"2013","unstructured":"Rabe K, Pageler L, Gaul C, Lampl C, Kraya T, Foerderreuther S, Diener HC, Katsarava Z (2013) Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study. Cephalalgia 33(3):202\u2013207. https:\/\/doi.org\/10.1177\/0333102412462638","journal-title":"Cephalalgia"},{"issue":"4","key":"2161_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/pr9.0000000000000612","volume":"2","author":"KB Alstadhaug","year":"2017","unstructured":"Alstadhaug KB, Ofte HK, Kristoffersen ES (2017) Preventing and treating medication overuse headache. Pain Rep 2(4):e612. https:\/\/doi.org\/10.1097\/pr9.0000000000000612","journal-title":"Pain Rep"},{"issue":"1","key":"2161_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0612-2","volume":"17","author":"NL Find","year":"2016","unstructured":"Find NL, Terlizzi R, Munksgaard SB, Bendtsen L, Tassorelli C, Nappi G, Katsarava Z, Lainez M, Goicochea MT, Shand B (2016) Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. J Headache Pain 17(1):20. https:\/\/doi.org\/10.1186\/s10194-016-0612-2","journal-title":"J Headache Pain"},{"issue":"1","key":"2161_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1046\/j.1468-2982.1983.0301061.x","volume":"3","author":"M Wilkinson","year":"1983","unstructured":"Wilkinson M (1983) Treatment of the acute migraine attack\u2013current status. Cephalalgia 3(1):61\u201367. https:\/\/doi.org\/10.1046\/j.1468-2982.1983.0301061.x","journal-title":"Cephalalgia"},{"key":"2161_CR13","doi-asserted-by":"publisher","first-page":"726643","DOI":"10.3389\/fphar.2021.726643","volume":"12","author":"S Chautrakarn","year":"2021","unstructured":"Chautrakarn S, Khumros W, Phutrakool P (2021) Self-medication with over-the-counter medicines among the working age population in metropolitan areas of Thailand. Front Pharmacol 12:726643. https:\/\/doi.org\/10.3389\/fphar.2021.726643","journal-title":"Front Pharmacol"},{"key":"2161_CR14","doi-asserted-by":"publisher","unstructured":"Society IH . Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38 1:1-211. https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"key":"2161_CR15","volume-title":"Thai headache disorders practical guideline","author":"TH Society","year":"2022","unstructured":"Society TH (2022) Thai headache disorders practical guideline. Thanaplace, Bangkok"},{"issue":"4","key":"2161_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3988\/jcn.2008.4.4.158","volume":"4","author":"HE Shin","year":"2008","unstructured":"Shin HE, Park JW, Kim YI, Lee KS (2008) Headache impact test-6 (HIT-6) scores for migraine patients: their relation to disability as measured from a headache diary. J Clin Neurol 4(4):158\u2013163. https:\/\/doi.org\/10.3988\/jcn.2008.4.4.158","journal-title":"J Clin Neurol"},{"issue":"9","key":"2161_CR17","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1526-4610.2001.01156.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Stewart WF, Sawyer J, Edmeads JG (2001) Clinical utility of an instrument assessing migraine disability: the migraine disability assessment (MIDAS) questionnaire. Headache 41(9):854\u2013861","journal-title":"Headache"},{"issue":"3","key":"2161_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1526-4610.2008.01257.x","volume":"49","author":"S Cevoli","year":"2009","unstructured":"Cevoli S, Sancisi E, Grimaldi D, Pierangeli G, Zanigni S, Nicodemo M, Cortelli P, Montagna P (2009) Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache 49(3):412\u2013418. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01257.x","journal-title":"Headache"},{"key":"2161_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2147\/jpr.S46071","volume":"7","author":"ES Kristoffersen","year":"2014","unstructured":"Kristoffersen ES, Lundqvist C (2014) Medication-overuse headache: a review. J Pain Res 7:367\u2013378. https:\/\/doi.org\/10.2147\/jpr.S46071","journal-title":"J Pain Res"},{"issue":"2","key":"2161_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1046\/j.1526-4610.2003.03034.x","volume":"43","author":"SD Silberstein","year":"2003","unstructured":"Silberstein SD, McCrory DC (2003) Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 43(2):144\u2013166. https:\/\/doi.org\/10.1046\/j.1526-4610.2003.03034.x","journal-title":"Headache"},{"issue":"2","key":"2161_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/0333102414550416","volume":"35","author":"G Roberto","year":"2015","unstructured":"Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D\u2019Alessandro R, De Ponti F, Poluzzi E (2015) Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia 35(2):118\u2013131. https:\/\/doi.org\/10.1177\/0333102414550416","journal-title":"Cephalalgia"},{"issue":"2","key":"2161_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000047960","volume":"47","author":"HC Diener","year":"2002","unstructured":"Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ (2002) Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 47(2):99\u2013107. https:\/\/doi.org\/10.1159\/000047960","journal-title":"Eur Neurol"},{"issue":"4","key":"2161_CR23","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/ane.13475","volume":"144","author":"D D\u2019Amico","year":"2021","unstructured":"D\u2019Amico D, Grazzi L, Guastafierro E, Sansone E, Leonardi M, Raggi A (2021) Withdrawal failure in patients with chronic migraine and medication overuse headache. Acta Neurol Scand 144(4):408\u2013417. https:\/\/doi.org\/10.1111\/ane.13475","journal-title":"Acta Neurol Scand"},{"key":"2161_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s10194-015-0561-1","volume":"16","author":"B Shand","year":"2015","unstructured":"Shand B, Goicochea MT, Valenzuela R, Fadic R, Jensen R, Tassorelli C, Nappi G (2015) Clinical and demographical characteristics of patients with medication overuse headache in Argentina and Chile: analysis of the Latin American section of COMOESTAS project. J Headache Pain 16:83. https:\/\/doi.org\/10.1186\/s10194-015-0561-1","journal-title":"J Headache Pain"},{"issue":"9","key":"2161_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/0333102414521508","volume":"34","author":"C Tassorelli","year":"2014","unstructured":"Tassorelli C, Jensen R, Allena M, De Icco R, Sances G, Katsarava Z, Lainez M, Leston J, Fadic R, Spadafora S et al (2014) A consensus protocol for the management of medication-overuse headache: evaluation in a multicentric, multinational study. Cephalalgia 34(9):645\u2013655. https:\/\/doi.org\/10.1177\/0333102414521508","journal-title":"Cephalalgia"},{"issue":"9","key":"2161_CR26","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/head.13641","volume":"59","author":"M Viana","year":"2019","unstructured":"Viana M, De Icco R, Allena M, Sances G, H\u00f8jland JR, Katsarava Z, Lainez MJA, Fadic R, Goicochea MT, Nappi G et al (2019) Clinical subtypes of medication overuse headache - findings from a large cohort. Headache 59(9):1481\u20131491. https:\/\/doi.org\/10.1111\/head.13641","journal-title":"Headache"},{"issue":"12","key":"2161_CR27","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1016\/j.pain.2014.08.027","volume":"155","author":"S Hassan","year":"2014","unstructured":"Hassan S, Muere A, Einstein G (2014) Ovarian hormones and chronic pain: a comprehensive review. Pain 155(12):2448\u20132460. https:\/\/doi.org\/10.1016\/j.pain.2014.08.027","journal-title":"Pain"},{"issue":"1","key":"2161_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/AJP.0b013e318223622c","volume":"28","author":"L Nordeman","year":"2012","unstructured":"Nordeman L, Gunnarsson R, Mannerkorpi K (2012) Prevalence and characteristics of widespread pain in female primary health care patients with chronic low back pain. Clin J Pain 28(1):65\u201372. https:\/\/doi.org\/10.1097\/AJP.0b013e318223622c","journal-title":"Clin J Pain"},{"key":"2161_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.genm.2009.03.006","volume":"2","author":"VT Martin","year":"2009","unstructured":"Martin VT (2009) Ovarian hormones and pain response: a review of clinical and basic science studies. Gend Med 6 Suppl 2:168\u2013192. https:\/\/doi.org\/10.1016\/j.genm.2009.03.006","journal-title":"Gend Med 6 Suppl"},{"key":"2161_CR30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s10194-024-01925-w","volume":"25 1","author":"L Pellesi","year":"2024","unstructured":"Pellesi L, Garcia-Azorin D, Rubio-Beltr\u00e1n E, Ha WS, Messina R, Ornello R, Petrusic I, Raffaelli B, Labastida-Ramirez A, Ruscheweyh R et al (2024) Combining treatments for migraine prophylaxis: the state-of-the-art. J Headache Pain 25 1:214. https:\/\/doi.org\/10.1186\/s10194-024-01925-w","journal-title":"J Headache Pain"},{"key":"2161_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-017-0763-9","volume":"18 1","author":"S Cevoli","year":"2017","unstructured":"Cevoli S, Giannini G, Favoni V, Terlizzi R, Sancisi E, Nicodemo M, Zanigni S, Bacchi Reggiani ML, Pierangeli G, Cortelli P (2017) Treatment of withdrawal headache in patients with medication overuse headache: a pilot study. J Headache Pain 18 1:56. https:\/\/doi.org\/10.1186\/s10194-017-0763-9","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02161-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02161-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02161-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:40Z","timestamp":1759404280000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02161-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2161"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02161-6","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the Institutional Review Board of the Faculty of Medicine, Chiang Mai University (Study code: MED-2567-0195). All data from this study were fully anonymized, and confidentiality was maintained throughout the access process. Since the study data were collected as part of routine clinical care, the requirement for individual patient consent was waived by the Research Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read, critically revised, reviewed and approved the final version of this manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}